According to the Ministry, 85 pharmaceutical companies have reported revised MRPs for 1,364 anti-cancer formulations across 121 drugs as of November 8, 2026. Revised MRPs for 1,364 anti-cancer formulations save consumers about ₹3,540 crore annually, with price caps and verification via NPPA. Revised MRPs cut 1,364 anti-cancer drugs, saving ₹3,540 cr/year, with 679 brands slashed by over 50% and transparent pricing enforced nationwide.